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Feinstein studied 140 patients attending an MS clinic in Toronto, Canada. He found that 40 (29%) patients had thought about committing suicide and nine had attempted suicide. Among the entire group of 140 patients, about onethird had a history of major depression at some time. In comparing the 40 patients who had a history of suicidal intent with the 100 who did not, Feinstein discovered that there were no differences between the two groups in age, sex, duration or type of MS, physical disability, or cognitive impairment. However, the group with a history of suicidal intent were much more likely to have problems with depression. About one-third of the suicidal group had evidence of significant depression at the time of study, compared with only 2% in the nonsuicidal group. In addition, 83% of the suicidal group had a history of major depression at some time in their lives compared with only 18% of the nonsuicidal group.
There were several factors that seemed to predict suicidal intent, including having a history of living alone, a family history of mental illness, significant depression or anxiety at the time of testing, significant psychosocial stress, and a diagnosis at any time of major depression, anxiety disorder, or alcohol abuse. The three most important factors were living alone, severe depression, and history of alcohol abuse.
The study by Patten and Metz addressed the concern that a commonly used treatment for MS, ␤-interferon, might cause depression as a side effect. As part of a 3-year study comparing placebo vs one type of ␤-interferon, Patten and Metz assessed 365 MS patients every 6 months for depression. They found that patients receiving ␤-interferon were no more likely to be depressed than those receiving placebo, indicating that depression is not a common side effect of ␤-interferon treatment. They discovered that depression among MS patients fluctuates over time. This suggests that it is important for physicians caring for MS patients to evaluate for depression at each clinic visit. This is important because severe depression among MS patients often goes untreated. About one-third of MS patients that experience major depression or have suicidal thoughts never receive treatment for depression. MS patients with depression respond to treatment with antidepressants and psychotherapy. Depression is therefore a treatable cause of suffering among MS patients. Because it increases the risk of suicide, appropriate treatment can decrease the risk of MS patients committing suicide. It is very important for physicians to recognize and treat depression among their MS patients. Patients and family members also should report depressive symptoms to their physicians to aid in appropriate treatment. 
